Cargando…

Crosstalk with cancer-associated fibroblasts induces resistance of non-small cell lung cancer cells to epidermal growth factor receptor tyrosine kinase inhibition

Although lung cancers with activating mutations in the epidermal growth factor receptor (EGFR) are highly sensitive to selective EGFR tyrosine kinase inhibitors (TKIs), these tumors invariably develop acquired drug resistance. Host stromal cells have been found to have a considerable effect on the s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Choe, Chungyoul, Shin, Yong-Sung, Kim, Changhoon, Choi, So-Jung, Lee, Jinseon, Kim, So Young, Cho, Yong Beom, Kim, Jhingook
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4676617/ https://www.ncbi.nlm.nih.gov/pubmed/26676152 http://dx.doi.org/10.2147/OTT.S89659

Ejemplares similares

Loss of E-cadherin activates EGFR-MEK/ERK signaling, which promotes invasion via the ZEB1/MMP2 axis in non-small cell lung cancer
por: Bae, Gab-Yong, et al.
Publicado: (2013)

Pathogenesis of RON receptor tyrosine kinase in cancer cells: activation mechanism, functional crosstalk, and signaling addiction
por: Wang, Ming-Hai, et al.
Publicado: (2013)

Neuroendocrine Differentiation in Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
por: Chang, Youjin, et al.
Publicado: (2013)

Crosstalk between CCL7 and CCR3 promotes metastasis of colon cancer cells via ERK-JNK signaling pathways
por: Lee, Yeo Song, et al.
Publicado: (2016)

Pretreatment neutrophil‐lymphocyte ratio is not a significant prognostic factor in epidermal growth factor receptor‐mutant non‐small cell lung cancer patients treated with tyrosine kinase inhibitors
por: Sim, Sung Hoon, et al.
Publicado: (2015)

Predicting Recurrence Using the Clinical Factors of Patients with Non-small Cell Lung Cancer After Curative Resection
por: Lee, Hyun Joo, et al.
Publicado: (2009)

Circulating Aneuploid Cells Detected in the Blood of Patients with Infectious Lung Diseases
por: Kim, Hongsun, et al.
Publicado: (2017)

Corrigendum: Circulating Aneuploid Cells Detected in the Blood of Patients with Infectious Lung Diseases
por: Kim, Hongsun, et al.
Publicado: (2017)

Regulation of Fibroblast Cell Polarity by Src Tyrosine Kinase
por: Katoh, Kazuo
Publicado: (2021)

Usefulness of Bronchoscopic Rebiopsy of Non-Small Cell Lung Cancer with Acquired Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor
por: Goag, Eun Kyong, et al.
Publicado: (2018)

Concurrent Autophagy Inhibition Overcomes the Resistance of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Human Bladder Cancer Cells
por: Kang, Minyong, et al.
Publicado: (2017)

Crosstalk between cancer‐associated fibroblasts and immune cells in cancer
por: An, Yuanyuan, et al.
Publicado: (2019)

AQP3 Increases Intercellular Cohesion in NSCLC A549 Cell Spheroids through Exploratory Cell Protrusions
por: Min, Sol, et al.
Publicado: (2021)

Histological transformation from non-small cell to small cell lung carcinoma after treatment with epidermal growth factor receptor-tyrosine kinase inhibitor
por: Kim, Woo-Jin, et al.
Publicado: (2015)

Transglutaminase 2 Expression Predicts Progression Free Survival in Non-Small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
por: Jeong, Jae-Heon, et al.
Publicado: (2013)

Repeated Favorable Responses to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in a Case of Advanced Lung Adenocarcinoma
por: Kim, Eun-Young, et al.
Publicado: (2013)

Nomogram Predicting Clinical Outcomes in Non-small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
por: Keam, Bhumsuk, et al.
Publicado: (2014)

Role of IGF-Binding Protein 3 in the Resistance of EGFR Mutant Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitors
por: Choi, Yun Jung, et al.
Publicado: (2013)

Crosstalk between fibroblasts and T cells in immune networks
por: Lee, Byunghyuk, et al.
Publicado: (2023)

The crosstalk: Tumor-infiltrating lymphocytes rich in regulatory T cells suppressed cancer-associated fibroblasts
por: Fu, Zhixuan, et al.
Publicado: (2013)

Quantification of epidermal growth factor receptor (EGFR) mutation may be a predictor of EGFR‐tyrosine kinase inhibitor treatment response
por: Park, Ha Young, et al.
Publicado: (2016)

Role of Exosomes in Crosstalk Between Cancer-Associated Fibroblasts and Cancer Cells
por: Yang, Xi, et al.
Publicado: (2019)

Quantitative phosphoproteomic analysis reveals reciprocal activation of receptor tyrosine kinases between cancer epithelial cells and stromal fibroblasts
por: Wu, Xinyan, et al.
Publicado: (2018)

Clinical Characteristics and Continued Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Administration in EGFR-mutated Non-Small Cell Lung Cancer with Skeletal Metastasis
por: Hong, Sook-Hee, et al.
Publicado: (2016)

Tyrosine kinase signalling in breast cancer: Fibroblast growth factors and their receptors
por: Dickson, Clive, et al.
Publicado: (2000)

Epidermal growth factor receptor tyrosine kinase inhibitors
por: Ranson, M
Publicado: (2004)

Efficacy of epidermal growth factor receptor tyrosine kinase inhibitor in the treatment of patients with nonsmall cell lung cancer
por: Li, Xi, et al.
Publicado: (2023)

Correction: Role of IGF-Binding Protein 3 in the Resistance of EGFR Mutant Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitors
por: Choi, Yun Jung, et al.
Publicado: (2019)

Mitochondrial Variations in Non-Small Cell Lung Cancer (NSCLC) Survival
por: Wang, Zhaoxi, et al.
Publicado: (2015)

Concomitant T790M mutation and small‐cell lung cancer transformation after acquired resistance to epidermal growth factor receptor‐tyrosine kinase inhibitor
por: Fujita, Kohei, et al.
Publicado: (2016)

Does the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor differ according to the type of EGFR mutation in non-small cell lung cancer?
por: Choi, Yong Won, et al.
Publicado: (2017)

Proline-rich tyrosine kinase 2 mediates transforming growth factor-beta-induced hepatic stellate cell activation and liver fibrosis
por: Kim, Jonghwa, et al.
Publicado: (2020)

ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
por: Yoshida, Takeshi, et al.
Publicado: (2016)

Correction to: Quantitative phosphoproteomic analysis reveals reciprocal activation of receptor tyrosine kinases between cancer epithelial cells and stromal fibroblasts
por: Wu, Xinyan, et al.
Publicado: (2018)

Treatment of Non-small Cell Lung Carcinoma after Failure of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
por: Lee, Jae Cheol, et al.
Publicado: (2013)

TIMP-1 mediates TGF-β-dependent crosstalk between hepatic stellate and cancer cells via FAK signaling
por: Park, Sang-A, et al.
Publicado: (2015)

SOX2, a stemness gene, induces progression of NSCLC A549 cells toward anchorage-independent growth and chemoresistance to vinblastine
por: Choe, Chungyoul, et al.
Publicado: (2018)

Should Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Be Continued beyond Progressive Disease?
por: Kim, Young Hak, et al.
Publicado: (2011)

Cancer: An Oxidative Crosstalk between Solid Tumor Cells and Cancer Associated Fibroblasts
por: Arcucci, Alessandro, et al.
Publicado: (2016)

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Elderly Patients with Advanced Non-Small Cell Lung Cancer
por: Meriggi, F., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_c1nmkntpqpke3jp0su0vefnkpu